Literature DB >> 148936

High incidence of a concentration-dependent skin reaction in children treated with phenytoin.

J T Wilson, B Höjer, G Tomson, A Rane, F Sjöqvist.   

Abstract

A particularly high incidence of rash was seen in children with epilepsy treated with phenytoin. Ten children with untreated epilepsy were therefore included in a prospective study and given either 3 (group 1) or 6 (group 2) mg of phenytoin/kg body weight/day for five days followed by 6 mg/kg body weight/day for both groups. Four of the five children in group 2 compared with only one of the five in group 1 developed a rash seven to 12 days after the start of treatment. Patients with rashes had significantly higher plasma phenytoin concentrations. Whenever the phenytoin concentration was higher than 14 micromol/l on day 5 a rash occurred. These findings indicate that the generalised skin reaction is caused by a high body burden of phenytoin, which results from either a high load of the drug or a low clearance rate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 148936      PMCID: PMC1605360          DOI: 10.1136/bmj.1.6127.1583

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  17 in total

1.  Erythema bullosum malignans following dilantin therapy.

Authors:  G HELLER; M SLOANE
Journal:  Pediatrics       Date:  1950-05       Impact factor: 7.124

2.  Erythema multiforme exudativum (Stevens-Johnson syndrome) following sodium diphenylhydantoin therapy.

Authors:  L M Greenberg; D A Mauriello; A A Cinotti; J N Buxton
Journal:  Ann Ophthalmol       Date:  1971-02

3.  Severe cutaneous reactions to phenytoin.

Authors:  K P Dawson
Journal:  Arch Dis Child       Date:  1973-03       Impact factor: 3.791

4.  Diphenylhydantoin toxicity: dose-dependent blood dyscrasia.

Authors:  W A Parker; R J Gumnit
Journal:  Neurology       Date:  1974-12       Impact factor: 9.910

5.  Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin.

Authors:  L Lund
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  Micromethod for the determination of diphenylhydantoin in plasma and cerebrospinal fluid--a comparison between a gas chromatographic and a spectrophotometric method.

Authors:  A Berlin; S Agurell; O Borgå; L Lund; F Sjöqvist
Journal:  Scand J Clin Lab Invest       Date:  1972-05       Impact factor: 1.713

7.  Diphenylhydantoin fatal hepatic necrosis (a review of literature and report of a case treated with exchange transfusion).

Authors:  L T Ch'ien; R Ceballos; J W Benton
Journal:  Ala J Med Sci       Date:  1970-07

8.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

9.  Diphenylhydantoin--induced hepatic necrosis.

Authors:  G J Dhar; C A Pierach; P N Ahamed; R B Howard
Journal:  Postgrad Med       Date:  1974-07       Impact factor: 3.840

10.  Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers.

Authors:  N Gerber; R Lynn; J Oates
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

View more
  7 in total

Review 1.  Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.

Authors:  S R Knowles; L E Shapiro; N H Shear
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

2.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.

Authors:  N H Shear; S P Spielberg
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

Review 3.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 4.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

5.  Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

Authors:  P E Rolan; A J Mercer; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 6.  Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.

Authors:  Kalliopi Gerogianni; Aspasia Tsezou; Konstantinos Dimas
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.476

Review 7.  New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity.

Authors:  Munir Pirmohamed; David A Ostrov; B Kevin Park
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.